1. Famitinib in combination with concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: a phase 1, open‐label, dose‐escalation Study
   Qiuyan Chen et al, 2018, Cancer Communications CrossRef